Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Greenwich LifeSciences, Inc. (GLSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
36.09-1.10 (-2.96%)
At close: 4:00PM EDT
35.99 -0.10 (-0.28%)
After hours: 07:52PM EDT
Advertisement
Sign in to post a message.
  • S
    Stephens
    $SLS conversation
    FDA Approval First half of 22, starts in a few months, will shares get any cheaper? Are there any negative news possibilities that anyone knows of? What are the Near term Catalysts?Is the Cash position more solid now than ever?
    Collecting from the $200m licensee 3DMed, small burn, cash for a couple years in the bank - no serious dilution concerns, although I would love to see them sell 5m shares for 50M.

    Valuable clinical data scheduled Multiple trial readouts for Q4 / Early January
    2 Nps Trials In Q4 that are now Imminent Vadis for 60,000 DCIS patients
    and High Her2 3+ Phase 2B Nps combination trial with Herceptin - Virtually Identical to $GLSI
    2 Gps + Checkpoint Readouts
    Opdivo Mesothelioma data on an expanded patient cohort, existing data 35 weeks of OS vs 20 in BAT
    and Keytruda Ovarian cancer readout where all patients are surviving at 9 months, which is already equal to the Best Available treatments.
    I think Nps License Deal could double or triple the value of SLS
    Ceo said he was working on Partnerships for Additional combination trials
    Cantor Fitgerald institutional investors will begin Nibbling Imo
    Dr Levy Baylor Medical Director of Hematological Research Essentially confirmed GPs FDA approval is a lock, P3 is Open label, he is on the Steering Committee and he said "GPs is nothing short of spectacular"

    9 could be 90 in 6 - 9 months in my opinion
    Bullish
  • E
    Ez$
    $SLS conversation
    100% on the Licensing- Nov 15 In june's Corp update the Ceo was asked about NPS by all three analysts in the q&A. Each one, asked about it, interesting considering the Market seems not to Give Nps any value, though $GLSI Is worth $500. Nps Licensing was Jason McCarthys first question and the last analyst said something about the great potential with bio similars and so on and then the ceo cut him of and said " NO it's ROCHE. " Like it was a Done Deal. DID anyone else catch that???
    Combine that with last weeks Legal news and also the Aug commentary where he went out of his way to say there "would be an announcement very soon".

    I expect news: Nps combined wHerceptin reduced TNBC by 80%, in a phase 2b. Something there.
    Bullish
  • S
    Stephens
    $SLS conversation
    Downside Risk Vs the Upside Potential majorly imbalanced
    FDA Approval First half of 22, starts in a few months, will shares get any cheaper?
    Are there any negative news possibilities that anyone knows of? What are the Near term Catalysts?
    Is the Cash position more solid now than ever?
    Collecting from the $200m licensee 3DMed, small burn, cash for a couple years in the bank - no serious dilution concerns, although I would love to see them sell 5m shares for 50M.

    Valuable clinical data scheduled Multiple trial readouts for Q4
    2 Nps Trials In Q4 that are now Imminent Vadis for 60,000 DCIS patients
    and High Her2 3+ Phase 2B Nps combination trial with Herceptin - Virtually Identical to $GLSI
    2 Gps + Checkpoint Readouts
    Opdivo Mesothelioma data on an expanded patient cohort, existing data 35 weeks of OS vs 20 in BAT
    and Keytruda Ovarian cancer readout where all patients are surviving at 9 months, which is already equal to the Best Available treatments.
    I think Nps License Deal could double or triple the value of SLS
    Ceo said he was working on Partnerships for Additional combination trials
    Cantor Fitgerald institutional investors will begin Nibbling Imo
    Dr Levy Baylor Medical Director of Hematological Research Essentially confirmed GPs FDA approval is a lock, P3 is Open label, he is on the Steering Committee and he said "GPs is nothing short of spectacular"

    9 could be 90 in 6 - 9 months in my opinion
  • E
    Ez$
    $SLS conversation
    In june's Corp update the Ceo was asked about NPS by all three analysts in the q&A. Each one, asked about it, interesting considering the Market seems not to Give Nps any value, though $GLSI Is worth $500. Nps Licensing was Jason McCarthys first question and the last analyst said something about the great potential with bio similars and so on and then the ceo cut him of and said " NO it's ROCHE. " Like it was a Done Deal. DID anyone else catch that???
    Combine that with last weeks Legal news and also the Aug commentary where he went out of his way to say there "would be an announcement very soon".

    I expect news: Nps combined wHerceptin reduced TNBC by 80%, in a phase 2b. Something there.
    Bullish
  • S
    Stephens
    $SLS conversation
    Valuable clinical data scheduled Multiple trial readouts for Q4 / Early January
    2 Nps Trials In Q4 that are now Imminent Vadis for 60,000 DCIS patients
    and High Her2 3+ Phase 2B Nps combination trial with Herceptin - Virtually Identical to $GLSI
    2 Gps + Checkpoint Readouts
    Opdivo Mesothelioma data on an expanded patient cohort, existing data 35 weeks of OS vs 20 in BAT
    and Keytruda Ovarian cancer readout where all patients are surviving at 9 months, which is already equal to the Best Available treatments.
    I think Nps License Deal could double or triple the value of SLS
    Ceo said he was working on Partnerships for Additional combination trials
    Cantor Fitgerald institutional investors will begin Nibbling Imo
    Dr Levy Baylor Medical Director of Hematological Research Essentially confirmed GPs FDA approval is a lock, P3 is Open label, he is on the Steering Committee and he said "GPs is nothing short of spectacular"
  • R
    Real Immuno Investor 10
    $BMY conversation
    $SLS about to untap A couple few billion in Shareholder value with Gps+ Nivo Meso data "The average progression-free survival was 8.8 weeks. Median overall survival was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered at the end of 2021" {lol expects.. It HAS TO BE LONGER all patients are currently alive!! - same situ w Gps+Keytruda $MRK for OC)
    https://www.asbestos.com/news/2021/06/29/gps-vaccine-opdivo-mesothelioma/
    "Preliminary evidence from the Phase I trial of GPS administered as a combination therapy with nivolumab (Opdivo® $BMY) as a treatment for mesothelioma showed improvement in median survival of about half a year." ttps://www.asbestos.com/news/2021/06/29/gps-vaccine-opdivo-mesothelioma/
    https://www.biospace.com/article/sellas-reports-promising-data-from-combination-trials-in-ovarian-cancer-and-mesothelioma/

    Nps VADIS results due and the $GLSI Sister trial with Herceptin $RHHBY
    All reporting in Q4 which begins next week already
    Bullish
  • R
    Real Immuno Investor 10
    $sls $glsi moment of truth about happen
    Any Nps deal will cost glsi - its traded below its range oddly
    Bullish
  • S
    Super Trader
    This will pop big one day
    Bullish
  • D
    Dude
    $SLS conversation
    Greenwich price action acting like they are buying Nps now that the legal T's are crossed. "Stay Tuned an announcement very soon" is what the CEO said...... $GLSI Type Trial data Nps + Herceptin completed for a 4th Quarter readout. I have always found it remarkable the GLSI Data Last Dec 2020, that moved the market from 5 to 150, adding a billion in market cap, WAS PUBLISHED in 2018 -TNBC Final reduced cancer recurrence by 80%! https://pubmed.ncbi.nlm.nih.gov/33485895/
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    Patients know, docs know - r they getting Injections GPs or standard Chemo Infusion type drugs.
    Dr Levy Knows. Anyone paying attention now knows this is worth more than the current market gives it credit for. Same thing happened with $GLSI, We all knew, here were posting, over and over as we do.
    The Data, Phase 2b 100% DFS that launched it from 5 to 145 was publicly known for months ahead of time.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Patients know, docs know - r they getting Injections GPs or standard Chemo Infusion type drugs.
    Dr Levy Knows. Anyone paying attention now knows this is worth more than the current market gives it credit for. Same thing happened with $GLSI, We all knew, here were posting, over and over as we do.
    Bullish
  • Z
    Zafer
    This stock is low float 3.5 million and they will start phase 3 trials within Q4-2021. 5 year data is wonderfull prevrnting reoccurency of cancer means metastas which is more mortal. When they got phase 2 remember what happened and when they would pass phase 3 trials within 3 months image what can happen. Ceo stated possible buyouts or aggrement soon. Matter of time. There is insider buy by Ceo again on August 2021. It is one of the most logical investment to me.
    Bullish
  • j
    jim
    Is this down in an up market cuz nps got bought? $sls
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    The Data, Phase 2b 100% DFS that launched $glsi from 5 to 145 in 1 day was already publicly known for months, ahead of time. Just a little DD And attention will payoff bigly.
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    Ceo Aug 17 " only comment I would like to make, Please Stay Tuned. We should have an announcement her very soon on the Nps front. "
    $Glsi trades for $600M, Nps has always been considered a better drug.
    Bullish
  • R
    Real Immuno Investor 10
    $sls Beginning run to full value 10x 6-9 months from Fda P3 Approval / The Data, Phase 2b 100% DFS that launched $glsi from 5 to 145 in 1 day was already publicly known for months, almost a year ahead of time. Just a little DD And attention will payoff bigly!

    4 trial readouts in q4, Keytruda Herceptin Opdivo combos and another P2B George Peoples / Mittendorf trial like the $glsi trial that caused the $500M in additional market cap.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Ceo Aug 17 - 3 long weeks ago " only comment I would like to make, Please Stay Tuned. We should have an announcement here very soon on the Nps front. "
    $Glsi trades for $600M, Nps has always been considered a better drug.
    Bullish
  • E
    Ez$
    $SLS conversation
    Geez $glsi is $700M now and Nps is Better at activating t cells
  • T
    Trond
    Greenwich LifeSciences Initiated at Buy by HC Wainwright & Co.
    Bullish
  • j
    jim
    $SLS conversation
    Re Nps two weeks ago from the CEO "Please Stay tuned, update on licensing, we should be having news here very soon on the NPs front" $GLSI has a $500M Market cap- Nps is a better version of the GLSI drug, NPS Approved for TNBC Phase 3 and DCIS, combination Trial with Herceptin Phase 2b Trial High Her2 3+ like Glsi finishing now. SLS's Secondary Asset is worth 4x the current share price.
    Nps Licensing ‘announcement very soon’.
    Will change the whole SLS paradigm. Can be combined with everything, chemo, checkpoints monoclonals - $glsi does trade for $500M and has always been considered inferior.
    Bullish
Advertisement
Advertisement